Lyon’s Pioneering HIFU Treatment for Endometriosis: A Recent Standard of Care
In a significant advancement for women’s health, the Hospices Civils de Lyon (HCL) have announced that High Intensity Focused Ultrasound (HIFU) is now a “standard therapeutic” treatment for severe endometriosis, as of November 2025. This marks a turning point in managing the debilitating condition, offering a non-surgical alternative for patients seeking relief.
From Prostate Cancer to Endometriosis: A Serendipitous Discovery
The journey from utilizing HIFU for prostate cancer to applying it to endometriosis began in 2015, thanks to the pioneering work of Professor Gil Dubernard, head of the gynecology-obstetrics department at Croix Rousse Hospital. Initially developed in collaboration with the INSERM (LabTAU) and EDAP-TMS, the Focal One® device was repurposed to target endometrial lesions. The technique, 100% developed in Lyon, focuses ultrasound waves through the rectum to ablate the endometriosis tissue.
Minimally Invasive and Fertility-Preserving
Traditional endometriosis treatment often involves extensive surgery, carrying risks like urinary problems, fistula formation, and, in some cases, the temporary need for an artificial anus. HIFU offers a dramatically different approach – a non-invasive procedure with no scalpel, no scarring, and no stomies. The treatment itself takes only minutes, aiming to destroy the endometriosis lesion without damaging surrounding tissue.
Promising Results and Global First
Extensive studies involving over 140 patients between 2015 and 2024 have demonstrated the effectiveness and tolerance of HIFU treatment. The procedure received CE marking in March 2025. HCL is now the first center globally to offer HIFU for endometriosis as a routine treatment, with the capacity to treat up to 100 patients in its first year. The CHU of Toulouse is expected to follow suit soon.
The Future of HIFU and Reimbursement
While HIFU is currently reimbursed by French health insurance for prostate cancer treatment, reimbursement for endometriosis is still under discussion. Professor Dubernard is actively working with health authorities to establish a transitional reimbursement scheme and plans to launch a cost-effectiveness study to demonstrate the long-term benefits of the technique.
Patient Demand and Reduced Surgical Burden
Professor Dubernard notes a high level of patient demand for HIFU treatment, expressing hope that it will significantly reduce the number of surgical interventions required for endometriosis. This shift towards less invasive options represents a major step forward in patient care.
Did you know?
Endometriosis affects one in ten women of childbearing age, causing intense pain and, in some cases, debilitating symptoms.
FAQ
What is HIFU? HIFU stands for High Intensity Focused Ultrasound. It’s a non-invasive technique that uses ultrasound waves to destroy targeted tissue.
Is HIFU suitable for all types of endometriosis? Currently, HIFU is most effective for endometriosis affecting the rectum.
Does HIFU affect fertility? HIFU is a fertility-preserving treatment option, unlike some surgical procedures.
Is HIFU painful? The procedure is generally well-tolerated, with minimal discomfort reported by patients.
Pro Tip
If you are experiencing symptoms of endometriosis, discuss all treatment options with your healthcare provider to determine the best course of action for your individual needs.
Learn more about endometriosis and available treatments at Hospices Civils de Lyon.
Have questions about HIFU or endometriosis? Share your thoughts in the comments below!
Related reading
- Azithromycin for Unscheduled C-Sections: New Study Analysis
- NYC COVID Hospitalizations Rising: How to Protect Yourself
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)